Goldman Sachs Initiates Coverage on Stoke Therapeutics with Buy Rating and $44 Price Target The firm sees strong potential for zorevunersen in treating Dravet syndrome. Credit: Stoke Therapeutics Subscribe now Already have an account? Sign in.
